1. What is Retatrutide?

Retatrutide is an investigational triple hormone receptor agonist targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. Designed for the management of obesity and type 2 diabetes, Retatrutide represents a next-generation incretin therapy that integrates appetite suppression, enhanced insulin function, and lipid oxidation to deliver broad-spectrum metabolic benefits.

2. Retatrutide Structure

Sequence:YA1QGTFTSDYSIL2LDKK4AQA1AFIEYLLEGGPSSGAPPPS3

Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈

Molecular Weight: 4731.33 g/mol

PubChem SlD: 474492335

CAS Number:2381089-83-2

Synonyms:LY-3437943,NOP2Y096GV

3. Retatrutide Research

Triagonist Mechanism

•  GLP-1R agonism: Reduces appetite and slows gastric emptying, improving satiety and postprandial glucose control.
•  GIPR agonism: Enhances insulin secretion and may improve pancreatic β-cell function.
•  GCGR stimulation: Increases energy expenditure, enhances lipid oxidation, and mobilizes fat stores.

Together, this three-receptor synergy remodels systemic metabolism, distinguishing Retatrutide from single or dual incretin analogues.

Key Clinical Findings

•  Weight Loss: Phase 2 trial results showed up to 24.2% mean body weight reduction at 48 weeks in obese individuals without diabetes.
•  Liver Fat Clearance: In MASLD patients, 93% normalized liver fat content with an 82% mean reduction at 24 weeks.
  【1】
•  Insulin Sensitivity: Consistent improvements in fasting insulin, HOMA-IR, and HbA1c observed across dosing cohorts.

Additional Observed Benefits

•  Triglycerides: Reductions exceeding 40% in high responders.
•  Adipokines: Favorable modulation of leptin, adiponectin, and β-hydroxybutyrate.
•  Fat Reduction: MRI scans confirm significant reductions in both visceral and subcutaneous adipose tissue.

✅ Why Consider Retatrutide?

💥 Superior weight-loss efficacy: Outperforms dual GLP-1/GIP analogs.

🧠 Central & peripheral effects: Appetite suppression + metabolic activation.

🔬 Three metabolic axes: GLP-1, GIP, and glucagon synergy for fat oxidation.

🩺 Cardio-hepatic benefits: Liver fat clearance, triglyceride reduction, and cardiovascular risk improvement.

🌐 Broad therapeutic scope: Obesity, T2D, MASLD/NASH, and metabolic syndrome.

4. Future Retatrutide Research

A. Long-Term Durability: Studies on maintenance of weight loss post-therapy and long-term cardiovascular safety.

B. Head-to-Head Comparisons: Direct comparisons with semaglutide, tirzepatide, and retatrutide in diverse populations.

C. Renal Protection: Trials investigating effects on diabetic nephropathy and kidney biomarkers.

D. Non-Diabetic Indications: Applications in prediabetes, PCOS, sleep apnea, and lipodystrophy.

E. Novel Delivery Systems: Oral, microneedle, and depot-release formulations for improved compliance.

F. AI-Guided Dosing Models: Precision titration based on liver, fat, and insulin biomarkers.

5. Application Areas

✅ Summary

Retatrutide is a first-in-class triple agonist peptide that combines GLP-1, GIP, and glucagon receptor activation for powerful metabolic remodeling. Clinical data highlight record-breaking weight loss, hepatic fat clearance, and broad metabolic improvements, establishing Retatrutide as one of the most promising future agents for obesity, diabetes, MASLD/NASH, and cardiometabolic disorders.

Disclaimer

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only (in vitro = outside of the body). These products are not medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.